Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
BB, Thanks for explaining. Useful information.
Being a naive individual investor, I could not understand if yesterday’s news was significant or not. I saw other posters mentioning it as wonderful. Hence, I posted my query. Yesterday’s uptick in NYSE could be due to various factors.
I think I've mentioned it before on here, but a lot of the RNS's Chimed issue are just RNS Reach's, and today's was another one.
For those that don't know ... an RNS Reach is basically information which should be viewed more as a Press Release than something which is deemed to be price sensitive. See https://www.lseg.com/areas-expertise/market-information/regulatory-news-service/rns-reach for more details.
If you just rely on this site ( lse ) to view RNS announcements, then there's nothing in the news section which makes it obvious if the news item is a regulatory requirement, or a Reach announcement. I've no idea why, it really wouldn't be that hard for them to do so.
If you want to know if it's a full RNS or just a Reach, then you need to go to a grown up site and look at something like https://www.londonstockexchange.com/stock/HCM/hutchison-china-meditech-limited/analysis where they make it obvious if it's a Reach.
Bottom line - if a Reach RNS is issued, then don't expect the sp to move because of it. Most of the grown ups will read it for what it is and pretty much ignore it. The sp might move up on a positive Reach RNS, so there could be a correlation there, but that doesn't necessarily link to cause
BB
Suspect this is just as expected....it is a positive development but is dependent on the US approval process. Edison expected a 2021 launch in Europe in their forecast.
Last weeks surge to 30+ will do for now. There was some retrenchment on Friday, so this news May help to shore up the SP around current levels rather than drifting back.
As usual LSE AIM market is oblivious to it. Wish our CEO had given a short statement about this item. Is it a good news for the company? We shall know in few hours time how the NYSE treats it as.
womderful! thankyou so much for posting that jatw
https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/data-and-statistics
Summary below.....Europe is a large oncology market.....of course there are many different forms of the disease and treatments with pricing closer to US than China it is also a profitable opportunity. The EMA news is welcome, not much extra expense (no trials needed) and bringing forward sales can only be a good thing for patients (with limited or no other options) and the company.
With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe. On a global scale, cancer accounted for 8.2 million deaths (around 13% of the total) in 2012.
Tobacco consumption and excessive alcohol consumption cause about 40% of the total cancer burden. The precise figures vary from country to country.
If the consequences of inappropriate diet, obesity and insufficient physical activity are added, the percentage of cancers due to an unhealthy lifestyle rises to 60%.
Although more than 40% of cancer deaths can be prevented, cancer accounts for 20% of deaths in the European Region.
Europe comprises only one eighth of the total world population but has around one quarter of the global total of cancer cases with some 3.7 million new patients per year.
Lung, breast, stomach, liver, colon and breast cancer cause the most cancer deaths each year.
Tobacco use is the single most important risk factor for cancer.
Fantastic news today regarding the EMA and Surufatinib registration. I tend to overlook the Europe and focus on what we are doing in the United States and China. I'm not sure what the size of the European market is for Oncology treatments, and probably need to research that a little, but it appears we could soon have Surufatinib submissions running concurrently in all 3 geographies.